Exited position

Stanley Druckenmiller’s Gilead Sciences Inc (GILD) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Duquesne Family OfficeVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2012Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares1.46MHighest verified quarter-end share count
Quarters reported9Verified quarters with shares above zero
What happened?

Duquesne Family Office first reported Gilead Sciences Inc in Q2 2012. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Duquesne Family Office sold the entire position in Q1 2019, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2019
Sold the entire position−1.02M shares · No shares reported at quarter-end
Q4 2018
Sold 30.1% of the position−441.56K shares · 1.02M shares remained
Filing context

Quarter-end price $62.55 · Estimated holding basis $71.97

Q3 2018
Bought 21.5% more+259.60K shares · 1.46M shares reported after the change
Filing context

Quarter-end price $77.21 · Estimated holding basis $71.97

Q2 2018
New position+1.21M shares · 1.21M shares reported
Filing context

Quarter-end price $70.84 · Estimated holding basis $70.84

Q4 2014
Sold the entire position−217.50K shares · No shares reported at quarter-end
Q3 2014
New position+217.50K shares · 217.50K shares reported
Filing context

Quarter-end price $106.45 · Estimated holding basis $106.45

1 unchanged quarter is collapsed by default.

Portfolio importance

How important was Gilead Sciences Inc in Duquesne Family Office’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight3.9%Q4 2018
Last reported rank#9of 30 reported positions
Peak portfolio weight5.4%Q3 2018
Best historical rank#6Q3 2018
At peak importanceQ3 2018
GILD
5.4%
Largest holding
19.2%
Cross-investor discovery

Who else owns Gilead Sciences Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Ray DalioBridgewater Associates, LP
GILD0.2% of reported portfolio
Joel GreenblattGotham Asset Management
GILD0.1% of reported portfolio
Explore Gilead Sciences Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$146.412026-09-14

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Duquesne Family Office LLC’s Form 13F disclosures—not Stanley Druckenmiller’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.